Fraktioneret CO2 laser-assisteret fotodynamisk terapi versus keratolytisk behandling af terapiresistente fodvorter

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-020933-25-DK

Enrollment

Registered

2010-07-23

Start date

2010-12-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recalcitrant plantar viral warts MedDRA version: 12.1 Level: LLT Classification code 10035158 Term: Plantar warts

Interventions

Trade Name: Metvix creme 16% Product Name: Metvix Product Code: 32850 Pharmaceutical Form: Cream INN or Proposed INN: methyle aminolevulinate CAS Number: 79416-27-6 Current Sponsor code: VEK26087 Othe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recalcitrant plantar warts for more than 3 months Age over 18 years Fertile women must use safe contraceptive medicine/method Must be able to attend to study treatments Informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Immunosuppression Pregnant or lactating women Previous Metvix treatment for the plantar warts Allergies towords the study IMPs Porphyria Patients who development of keloids

Design outcomes

Primary

Measure	Time frame
Main Objective: Clearance rate of plantar warts at end of study compared to baseline;Secondary Objective: Pain associated with Metvix photodynamic therapy Adverse events ;Primary end point(s): Number of plantar warts at end of study compared to baseline Pain related to photodynamic therapy Number and severity of adverse events	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026